Skip to content
FORSIDEN
Log ind Opret konto
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Genmab
  4. Genmab — September 2024

Genmab — September 2024

Planlagt Fastgjort Låst Flyttet Genmab
1.1k Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • E Offline
    E Offline
    E_L
    wrote on sidst redigeret af
    #88

    i think it is fair to say that the JNJ opt-in speed and the trial speed for Hexa-cd38 was misjudged from the start. And there are plenty of explanations for that, like slow/difficult recruitment due to covid, but also due to the ridiculous success of Dara (making it so hard to find Dara naive patients), the arbitration offcourse and the strategic importance of this for JNJ.

    1 Reply Last reply
    0
    • E Offline
      E Offline
      E_L
      wrote on sidst redigeret af
      #89

      I think that Genmab could have explained a bit better the potential for GEN3014 outside of the area reserved for JNJ , to decrease the risk of the JNJ opt-in.

      1 Reply Last reply
      0
      • E Offline
        E Offline
        E_L
        wrote on sidst redigeret af
        #90

        But right now i don't really need that anymore as we will probably know in 6 month or so what will happen and in that time we will also see data for Acasunlimab and Rina-S. We need to wait for that anyway. And i also think that potential Acasunlimab success/good data could completely revalue some of the other pipeline assets.

        1 Reply Last reply
        0
        • E Offline
          E Offline
          E_L
          wrote on sidst redigeret af
          #91

          The Inclacumab trial completed, curious if we will see anything on this https://clinicaltrials.gov/study/NCT04935879?tab=history&a=11&b=12&compareMode=sideBySide#version-content-panel

          1 Reply Last reply
          0
          • SolsenS Offline
            SolsenS Offline
            Solsen
            wrote on sidst redigeret af
            #92

            Winkel did talk about the patent issue for faspro. The extension the bastards got and that became the achillesheal for the shareprice. He said if JNJ should get rid of that uncertainty they should op.in on hexa38. He was refering to a Novo issue about this. Do anyone have somthing about that ?

            1 Reply Last reply
            0
            • E Offline
              E Offline
              E_L
              wrote on sidst redigeret af
              #93

              PRV-015 also completed https://clinicaltrials.gov/study/NCT04424927?tab=history&a=24&b=25&compareMode=sideBySide#version-content-panel

              1 Reply Last reply
              0
              • E Offline
                E Offline
                E_L
                wrote on sidst redigeret af
                #94

                https://www.nejm.org/doi/full/10.1056/NEJMc2407150 https://www.nejm.org/doi/full/10.1056/NEJMc2408786 Can't read these, but 2 NEJM articles on Teclistamab in Autoimmune Disease https://x.com/grieshaber/status/1831568931896623243 https://x.com/VivekSubbiah/status/1831537396837474654

                1 Reply Last reply
                0
                • S Offline
                  S Offline
                  Sukkeralf
                  wrote on sidst redigeret af
                  #95

                  Probably something to do with this EL

                  1 Reply Last reply
                  0
                  • S Offline
                    S Offline
                    Sukkeralf
                    wrote on sidst redigeret af
                    #96

                    Just a moment...

                    favicon

                    (www.fiercepharma.com)

                    1 Reply Last reply
                    0
                    • S Offline
                      S Offline
                      Sukkeralf
                      wrote on sidst redigeret af
                      #97

                      Solsen was it

                      1 Reply Last reply
                      0
                      • SolsenS Offline
                        SolsenS Offline
                        Solsen
                        wrote on sidst redigeret af
                        #98

                        Thanks. Havent seen this case. But recall fda challenge the patent if the drug isnt new in another case, I belive. These arguments are stong for our case hexa38, I belive 😉

                        1 Reply Last reply
                        0
                        • M Offline
                          M Offline
                          MarsFars
                          wrote on sidst redigeret af
                          #99

                          Hvornår er de forskellige konference, hvor vi får lidt flere data?

                          1 Reply Last reply
                          0
                          • SolsenS Offline
                            SolsenS Offline
                            Solsen
                            wrote on sidst redigeret af
                            #100

                            De første var vist om små
                            14 dage. Men der er en række konferencer. ESMO, ASCO etc ESMO 13-17. sep https://www.esmo.org/

                            1 Reply Last reply
                            0
                            • S Offline
                              S Offline
                              Sukkeralf
                              wrote on sidst redigeret af
                              #101

                              SITC 6-10 november og ASH 7-10 december

                              1 Reply Last reply
                              0
                              • S Offline
                                S Offline
                                Sukkeralf
                                wrote on sidst redigeret af
                                #102

                                Og så deres post ASH seminar i forbindelse med ASH, hvis de altså holder det i år

                                1 Reply Last reply
                                0
                                • SolsenS Offline
                                  SolsenS Offline
                                  Solsen
                                  wrote on sidst redigeret af
                                  #103

                                  https://finance.yahoo.com/news/biontech-present-clinical-data-updates-111500882.html Biontech flager nogle af indlæggene her

                                  1 Reply Last reply
                                  0
                                  • R Offline
                                    R Offline
                                    Raffles
                                    wrote on sidst redigeret af
                                    #104

                                    Den første interessante er World conference on Lung Cancer (WCLC) d 7-10 sept. Her kommer flere data på GEN1046/Acasunlimab. Vist nok d. 9. Sept.

                                    1 Reply Last reply
                                    0
                                    • P Offline
                                      P Offline
                                      ProinvestorNEWS
                                      wrote on sidst redigeret af
                                      #105

                                      Kort video: Investorernes største ønske i september er lidt som at blæse og have mel i munden. Økonomien skal bremse tilpas meget op, så inflationen går ned, men uden vi havner i en recession. Mere herom i denne ugekommentar, hvor Helge Larsen omtaler Bavarian Nordic, Ambu og Genmab.https://proinvestor.com/boards/122132

                                      1 Reply Last reply
                                      0
                                      • BulderB Offline
                                        BulderB Offline
                                        Bulder
                                        wrote on sidst redigeret af
                                        #106

                                        Post ASH ville være oplagt til offentliggørelse af top Line data på hex38.

                                        1 Reply Last reply
                                        0
                                        • SolsenS Offline
                                          SolsenS Offline
                                          Solsen
                                          wrote on sidst redigeret af
                                          #107

                                          Biontech flager næppe mere med 1046 efter at de droppede ud af den videre udvikling. Men de har en late breaker og flere mini orale indlæg på ESMO. Lad os se hvor Gen1046 lander.

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper